# A New Hope for Seizures Exploring CBD s Potential for Dogs with Epilepsy > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/a-new-hope-for-seizures-exploring-cbd-s-potential-for-dogs-with-epilepsy/ > **Published:** 2026-06-25T23:05:52-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:21:20-04:00 > **Clinical Summary:** Veterinary CBD research in canine epilepsy offers mechanistic insights for human seizure management. Learn what the evidence supports. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. CBDNeurologyResearchSafetyDosingHempAnxiety Why This Matters Clinicians treating canine patients with refractory epilepsy now have emerging evidence that CBD may reduce seizure frequency, offering a potentially safer alternative to conventional anticonvulsants that carry significant side effects. Understanding CBD’s mechanism in the canine [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) provides veterinary practitioners with a pharmacologically grounded rationale for considering this treatment option when standard therapies fail or are poorly tolerated. This evidence also informs human neurology by demonstrating how cannabinoids interact with mammalian seizure pathways, potentially accelerating [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) in pediatric epilepsy where conventional drugs similarly have limited efficacy. Clinical Summary Preclinical and observational evidence suggests that cannabidiol (CBD) may have anticonvulsant properties in canine epilepsy, a finding supported by the presence of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) receptors across mammalian species including dogs. While FDA-approved CBD (Epidiolex) has demonstrated efficacy in human pediatric seizure disorders, veterinary applications remain largely anecdotal, with limited controlled trials establishing safety and efficacy in dogs. The mechanistic rationale for CBD’s anticonvulsant effects likely involves modulation of endocannabinoid signaling and other pathways relevant to seizure suppression, though the optimal dosing, formulation, and patient selection criteria for veterinary use remain undefined. For clinicians treating human patients, this work reinforces the growing body of evidence supporting cannabinoid mechanisms in seizure control and may inform discussions with pet-owning patients about their animals’ treatment options. The practical takeaway is that while CBD shows promise as an adjunctive or alternative seizure therapy across species, veterinary patients would benefit from clinician awareness of this emerging evidence, though evidence-based recommendations for dogs still require additional controlled research. Dr. Caplan’s Take “The early signals here are worth watching, particularly because the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) is conserved across mammals, but we need rigorous, placebo-controlled trials in veterinary medicine before we can meaningfully advise dog owners that CBD is an effective seizure treatment rather than an experimental option.” Clinical Perspective 🧠 While cannabidiol (CBD) has shown promise in human [epilepsy management](https://cedclinic.com/cannabinoid-like-compound-seizure-reduction/), particularly for treatment-resistant seizures, the translational application to veterinary patients requires careful consideration of species-specific pharmacokinetics, dosing standardization, and regulatory status. The canine endocannabinoid system shares fundamental similarities with humans, supporting the biological plausibility of CBD efficacy in dogs, yet most veterinary [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) remain unregulated and lack rigorous pharmacokinetic or efficacy data in animal populations. Clinicians should be aware that pet owners increasingly seek CBD as an adjunctive or [alternative therapy](https://cedclinic.com/cannabis-for-chronic-pelvic-pain-self-management/) for canine seizure disorders, sometimes alongside or instead of evidence-based anticonvulsants, which may delay more proven interventions. In practice, veterinarians and human clinicians working with pet-owning patients should remain informed about this emerging area, acknowledge the limited evidence base, and encourage owners to discuss any 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20A%20New%20Hope%20for%20Seizures%20Exploring%20CBD%20s%20Potential%20for%20Dogs%20with%20Epilepsy%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66773)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66773)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20A%20New%20Hope%20for%20Seizures%20Exploring%20CBD%20s%20Potential%20for%20Dogs%20with%20Epilepsy%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66773)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [In the Mix: 31 More Articles — June 23, 2026](https://cedclinic.com/31-cannabis-articles-clinical-relevance-june-23-2026/) - [Michigan’s $3B Cannabis Industry Faces Pressure Amid Tax Repeal Push](https://cedclinic.com/cannabis-tax-repeal-impact-michigan-industry-pressure/) - [CBD improves neuropsychiatric symptoms in tuberous sclerosis complex: EpiCom trial insights](https://cedclinic.com/cbd-neuropsychiatric-symptoms-tuberous-sclerosis-epicom-trial/) 📰 Source: [https://www.petage.com/seizures-cbd-dogs-epilepsy/](https://www.petage.com/seizures-cbd-dogs-epilepsy/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).